. 2024 Apr 22;10(9):e30001. doi: 10.1016/j.heliyon.2024.e30001

Table 3.

Class 1 (red) doctors and pharmaceuticals’ approach.

	Words	Interviews	Issue	Attribute	References
Impact on MS diagnosis	project, short, step	Doctor 1: ‘The main barrier of the project is economical.’	Barriers	Financing and cost trade-offs	[94,95]
	project, short, step	Doctor 2: ‘More than giving more life expectancy is trying to shorten the progression of disability as much as possible.’		Financing and cost trade-offs	[94,95]
	information, time	Doctor 1: ‘That it does not make me waste time in the consultation and that it does not mess us up.’		Challenges about skills for digitalisation	[32,42]
	information, time	Doctor 6: ‘We also need information useful and understandable by the neurologist.’		Challenges about skills for digitalisation	[32,42]
	interest, participate	Doctor 3: ‘It will give them information on how their disease is controlled. They will want to participate.’	Drivers	Adherence of MS patients to PSS	[42,91]